overall survival
The proportion of patients still alive at a given time point (e.g., 10 years), the meaningful metric distinct from median survival.
As defined in Peter Attia on Lifespan, Healthspan, and Outlive
Where it comes up · 3
- Vinay Prasad on Cancer Drugs, Medical Ethics, and Malignant2 claims
- Vinay Prasad on Pharmaceuticals, the FDA, and the Death of Duty1 claim
- Peter Attia on Lifespan, Healthspan, and Outlive1 claim
Most important claims · 4 of 4Search all claims for “overall survival” →
- For a disease like multiple myeloma with 10-15 active drugs and 7-10 year median survival, drugs should not be approved on uncontrolled tumor-shrinkage studies; instead the bar should be improved survival over a real American standard of care, and ideally a clinically meaningful threshold (three to six months) that patients consider worthwhile.Vinay Prasad on Pharmaceuticals, the FDA, and the Death of Duty
- Despite the 1971 war on cancer, overall survival for metastatic solid-organ cancer has improved only from roughly 0% to about 1% alive at 10 years, with only testicular cancer and a rare GI stromal tumor curable today; overall cancer survival is up only 8-10% in 50 years, though median survival and outcomes for leukemias/lymphomas have improved substantially.Peter Attia on Lifespan, Healthspan, and Outlive
- Although exceptional success stories like Imatinib, Rituximab, and Trastuzumab exist, an empirical and broad look at cancer drugs shows they offer marginal benefits—the median improvement in overall survival across 71 consecutively-approved solid-tumor drugs was 2.1 months—while costing $12-16,000 per month for indefinite, non-curative treatment, producing very poor value.Vinay Prasad on Cancer Drugs, Medical Ethics, and Malignant
- Of 100 consecutive oncology drug approvals, only about a third improve overall survival or quality of life; a third merely delay progression-free survival, which only gives the illusion of being meaningful because it rests on arbitrary radiographic cut-offs; and a third are approved on single-arm studies with no control arm using response rate—so approving drugs on these surrogate endpoints means many likely do not improve survival or quality of life.Vinay Prasad on Cancer Drugs, Medical Ethics, and Malignant